Biotek-snakken — Marts 2021
-
Orphazyme's Arimoclomol trial failure in the treatment of inclusion body myositis is a major setback for the company, Bank of America analysts said, downgrading the stock to underperform from buy.
• There is no clear path forward in IBM for the drug: BofA
• Price target cut to $5 from $13
• Arimoclomol has another shot with an ongoing phase 3 study in ALS, with results expected before the summer, BofA said -
Velbekomme da:)
-
@Svingtraderen - godt vi kan hjælpe hinanden her på PI, selvom vi står på hver sin side. Du har vist aktien, jeg ikke
-
BioNTech forventer en omsætningsandel på 9,8 mia euro for de allerede solgte 1,4 mia doser vaccine. For de 2,5 mia doser, de planlægger i 2021, vil det betyde en omsætning på 17,5 mia euro. Det svarer cirka til deres markedsværdi.
https://investors.biontech.de/news-releases/news-release-details/biontech-announces-full-year-2020-financial-results-and -
@exitnu - 100% enig - vigtigt at dele kursdrivende info o
g det er uanset position - og ja jeg har den sønderskudte aktie:) -
Det er her hjælp til selvhjælp -
-
som jeg skrev 9:37 i Orpha - går efter 60 - der er vi så nu
-
Tak - solgte de ekstra:) Hold strategien
-
hvorfor stiger den 50% i us og har været børsstoppet 2 gange
-
Godt set - må være fat finger
-
selvom volumen er høj
-
@84,25 - nogen er på stoffer..
-
handles i USD 11@ 69,85 - fatter brik
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind